Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. - Wikidata - wikimedia - TriplyDB

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.

http://www.wikidata.org/entity/Q36477818

about

Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling.Pericytes, an overlooked player in vascular pathobiology Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Microenvironmental regulation of tumour angiogenesis.A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models.Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.The role of tumor microenvironment in resistance to anti-angiogenic therapy.IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma.Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality.Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.

P2860

Q27322343-99CDC599-A0A4-4FEF-92A7-A7C75E15A54E Q28070053-0B978832-3C7B-423E-ACD3-549796714D85 Q28070234-B6E988FF-0B3D-4D32-ACE9-0449A2C5B028 Q33853991-A2561D10-76DB-4743-BD92-9C707A83C60C Q37138981-AB7D4E09-B691-4968-BF10-E3EE4C16E2F4 Q37567174-40D00076-182A-467F-8B04-E25165631958 Q38675589-5C1FA2A9-3AEA-4B72-BEAE-32217EB3A96D Q38707904-553DC361-2013-4CB7-A44E-245F8ADEE03B Q38736319-8EDA523F-26CF-4FAB-971B-D08EAEEAD526 Q39022941-9F4254EF-56B0-4926-81DB-1575EB876C77 Q39433862-CBBA7FEA-F8DB-4E49-80FF-2D5FED6EF8CB Q41574359-0F2C4A5C-E170-4571-9778-EFF75E504736 Q48369496-6D8CB7DB-62BA-45E0-AA46-6BD86C6EA8FE Q50216662-111F79C4-8592-4E4C-A7F1-48B0D69B469D Q51731320-B7F77C2B-62A4-4434-8C99-933C13A398B1 Q52579594-6AC3B04B-16A3-4297-815C-1C7F98A91741 Q52645823-80BFB900-4021-466B-8922-289AB90A6D02 Q52719932-A3F414B9-876D-47B2-BC51-38421385267D Q53082876-78249FE0-DFEA-4661-B7F8-77B600911ED8 Q55012033-E7668EBD-3AC7-47E0-B5F2-4B126E61183B Q55190117-96668DB8-7CD0-489D-93AB-E798D9252E8F Q55349951-199F9E45-1D94-44A7-AC11-68BFA97803BB

P2860

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.

http://www.wikidata.org/entity/Q36477818

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Endothelial cell-derived angio ...... izumab-resistant glioblastoma.

@ast

Endothelial cell-derived angio ...... izumab-resistant glioblastoma.

@en

type

label

Endothelial cell-derived angio ...... izumab-resistant glioblastoma.

@ast

Endothelial cell-derived angio ...... izumab-resistant glioblastoma.

@en

prefLabel

Endothelial cell-derived angio ...... izumab-resistant glioblastoma.

@ast

Endothelial cell-derived angio ...... izumab-resistant glioblastoma.

@en

P1433

Q36477818-1A6712B6-DECB-494F-95A4-3DDECCCF9CAA

P1476

Q36477818-64E2CBCC-3B8C-447D-BE22-67C258FB7AB5

P2093

Q36477818-02D82B0C-803B-4160-9D3A-8E3E5B4F4CA4

Q36477818-0B5360EE-FB82-4149-97D9-6445764AE9E4

Q36477818-0D6E47EB-30C9-4BFA-8D0C-938E0C7189C9

Q36477818-0F5A702D-458B-4EB4-AAD0-2BD137943807

Q36477818-1116805E-1F5E-4F8C-AEFF-D82CA152B1B4

Q36477818-25981E34-98C3-45D3-9B3A-85C3C2494EA3

Q36477818-33DA6914-8D78-41D0-9960-765062AEAC05

Q36477818-360B60FE-CF83-4F62-952F-8B3CF3DB156E

Q36477818-4C4F5BEE-56EF-4FD9-A1F9-18D17897E189

Q36477818-534C3DC3-222D-4AF5-8F6D-15B8A35D1D1C

P2860

Q36477818-0E42DEEE-621B-4C43-A424-36B40DAA22BD

Q36477818-1939E6D8-6CBE-4211-A3FD-CA0280A313A9

Q36477818-1A5262A5-D81B-4F4B-9F9A-927D10B67AC6

Q36477818-1B0EE56E-AEB8-4DCE-90DE-35AD7328079D

Q36477818-1B180189-A0E3-4635-8F6C-D4D7B8E37AFB

Q36477818-1B76079B-B858-4FFD-AC42-E8DA58F00C35

Q36477818-22EFF483-B475-442A-8484-5399F86F95B7

Q36477818-2C39B8A3-9553-455D-A81B-84E6BE5F8319

Q36477818-2C74196B-3458-40CD-A527-466FC27AD0F6

Q36477818-3157DFAB-3F17-4987-AC15-FF309E9A074A

P304

Q36477818-AC2CC5BF-15E2-4DEB-ADE2-0F4349B25DEE

P31

Q36477818-56E7F360-AB0F-4615-A3CF-48DB606EBE74

P356

Q36477818-145CF812-DB8F-49FD-8C90-9C6007F64CFC

P433

Q36477818-D4F08ACE-6038-4074-A748-540C4C379C5D

P478

Q36477818-1B984CC9-CCD6-4817-B85D-1D83704E20A6

P50

Q36477818-68AF1175-840B-4FFC-8FE2-734D1F3AFDF7

Q36477818-9AD62BC0-B565-47BE-902C-DEBBE005C587

Q36477818-EC0E9C1A-6D4A-4833-AACD-C2D67E1E96B5

Q36477818-F3477FA2-4D19-488E-8088-DFDD85C33426

P577

Q36477818-1AD26774-F730-4E36-8BE0-702E8FB2047F

P5875

Q36477818-ACFEBC8C-81A5-471D-9A59-25F55815B4D4

P698

Q36477818-F14B913E-8C81-4C7B-BF2F-0C4CC70F0D22

P921

Q36477818-79A70928-8DD0-46BF-9AB5-A91E0010C183

Q36477818-9E4CBE29-871C-49EC-9929-B83AB4E51EDE

P932

Q36477818-D1E76844-044B-44E9-857E-00E1DF49EA30

P356

P1433

EMBO Molecular Medicine

P1476

Endothelial cell-derived angio ...... izumab-resistant glioblastoma.

@en

P2093

Alexander Scholz

http://www.w3.org/2001/XMLSchema#string

Astrid Weyerbrock

http://www.w3.org/2001/XMLSchema#string

Burak H Yalcin

http://www.w3.org/2001/XMLSchema#string

Christian Braun

http://www.w3.org/2001/XMLSchema#string

Dietmar Krex

http://www.w3.org/2001/XMLSchema#string

Joachim P Steinbach

http://www.w3.org/2001/XMLSchema#string

Jochen T Frueh

http://www.w3.org/2001/XMLSchema#string

Jörg Trojan

http://www.w3.org/2001/XMLSchema#string

Karl H Plate

http://www.w3.org/2001/XMLSchema#string

Kathleen Sommer

http://www.w3.org/2001/XMLSchema#string

P2860

Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

The 2007 WHO classification of tumours of the central nervous system

Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

P304

39-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15252/EMMM.201505505

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Jens Schittenhelm

Patrick N. Harter

Michel Mittelbronn

P577

2015-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287203983

http://www.w3.org/2001/XMLSchema#string

P698

26666269

http://www.w3.org/2001/XMLSchema#string

P921

P932

4718155

http://www.w3.org/2001/XMLSchema#string